ARQT - FDA Approves Arcutis Biotherapeutics' Lead Drug For Scaly Skin Disorder | Benzinga
The FDA approved Arcutis Biotherapeutics Inc's (NASDAQ: ARQT) Zoryve (roflumilast) topical foam, 0.3% for seborrheic dermatitis in individuals nine years and older.
Zoryve is a once-daily steroid-free foam and the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades.
Seborrheic dermatitis affects more than 10 million people in the U.S. and is a common, chronic, and recurrent inflammatory skin disease that causes red patches covered ...